BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24859441)

  • 1. Low detectable prostate specific antigen after radical prostatectomy--treat or watch?
    Koulikov D; Mohler MC; Mehedint DC; Attwood K; Wilding GE; Mohler JL
    J Urol; 2014 Nov; 192(5):1390-6. PubMed ID: 24859441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
    J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
    Woon DTS; Herrera-Cáceres JO; Goldberg H; Shiakh H; Whelan E; Nason G; Ajib K; Tan GH; Chandrasekar T; Alhunaidi O; Finelli A; Zlotta A; Berlin A; Diamantis E; Fleshner N
    J Urol; 2020 Aug; 204(2):289-295. PubMed ID: 32068483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
    Liesenfeld L; Kron M; Gschwend JE; Herkommer K
    J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
    Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
    J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer biochemical recurrence rates after robotic-assisted laparoscopic radical prostatectomy.
    Ginzburg S; Nevers T; Staff I; Tortora J; Champagne A; Kesler SS; Laudone VP; Wagner JR
    JSLS; 2012; 16(3):443-50. PubMed ID: 23318071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
    Patel A; Dorey F; Franklin J; deKernion JB
    J Urol; 1997 Oct; 158(4):1441-5. PubMed ID: 9302139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy.
    Smith JA; Chan RC; Chang SS; Herrell SD; Clark PE; Baumgartner R; Cookson MS
    J Urol; 2007 Dec; 178(6):2385-9; discussion 2389-90. PubMed ID: 17936849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?
    Toussi A; Stewart-Merrill SB; Boorjian SA; Psutka SP; Thompson RH; Frank I; Tollefson MK; Gettman MT; Carlson RE; Rangel LJ; Karnes RJ
    J Urol; 2016 Jun; 195(6):1754-9. PubMed ID: 26721226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we stop prostate specific antigen testing 10 years after radical prostatectomy?
    Loeb S; Feng Z; Ross A; Trock BJ; Humphreys EB; Walsh PC
    J Urol; 2011 Aug; 186(2):500-5. PubMed ID: 21679999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen.
    Matsumoto K; Komatsuda A; Yanai Y; Niwa N; Kosaka T; Mizuno R; Kikuchi E; Miyajima A; Oya M
    J Urol; 2017 Mar; 197(3 Pt 1):655-661. PubMed ID: 27590477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
    Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
    J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.
    Shikanov S; Song J; Royce C; Al-Ahmadie H; Zorn K; Steinberg G; Zagaja G; Shalhav A; Eggener S
    J Urol; 2009 Jul; 182(1):139-44. PubMed ID: 19450829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of Gleason score on biochemical recurrence free survival after radical prostatectomy with positive surgical margins].
    Roux V; Eyraud R; Brureau L; Gourtaud G; Senechal C; Fofana M; Blanchet P
    Prog Urol; 2017; 27(8-9):467-473. PubMed ID: 28576421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy.
    Ploussard G; Staerman F; Pierrevelcin J; Saad R; Beauval JB; Roupret M; Audenet F; Peyromaure M; Delongchamps NB; Vincendeau S; Fardoun T; Rigaud J; Villers A; Bastide C; Soulie M; Salomon L;
    J Urol; 2013 Nov; 190(5):1750-6. PubMed ID: 23643600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.